Correspondence to: Bernardo Cortese, MD, FESC, Interventional Cardiology, A.O. Fatebenefratelli Milano, Bastioni di Porta Nuova 21, 20100 Milano, Italy. E-mail: [email protected]Search for more papers by this author

Roberto Adriano Latini MD,

Roberto Adriano Latini MD

Interventional Cardiology, Azienda Ospedaliera Fatebenefratelli, Milano, Italy

Search for more papers by this author

Francesco Granata MD,

Francesco Granata MD

Interventional Cardiology, Azienda Ospedaliera di Nola, Nola, Italy

Search for more papers by this author

Alfonso Ielasi MD,

Alfonso Ielasi MD

Cardiology Division, Azienda Ospedaliera Bolognini, Seriate (BG), Italy

Search for more papers by this author

Attilio Varricchio MD,

Attilio Varricchio MD

Interventional Cardiology, Azienda Ospedaliera di Nola, Nola, Italy

Search for more papers by this author

Elisabetta Moscarella MD,

Elisabetta Moscarella MD

Interventional Cardiology, Azienda Ospedaliera di Nola, Nola, Italy

Search for more papers by this author

Maurizio Tespili MD,

Maurizio Tespili MD

Cardiology Division, Azienda Ospedaliera Bolognini, Seriate (BG), Italy

Search for more papers by this author

Bernardo Cortese MD, FESC,

Corresponding Author

Bernardo Cortese MD, FESC

[email protected]

Interventional Cardiology, Azienda Ospedaliera Fatebenefratelli, Milano, Italy

First published: 01 April 2016

https://doi.org/10.1002/ccd.26516

Citations: 10

Conflict of interest: Nothing to report.

Share a link

Email
Wechat
Bluesky

Abstract

Objective

In this study, we investigated long-term results following bioresorbable vascular scaffold (BVS) implantation in small coronary arteries.

Background

Management of small coronary vessel disease with percutaneous coronary interventions (PCI) is often associated with high recurrencies and an increased risk of late or very late adverse events. Currently, little is known about BVS behavior in this setting.

Methods

A retrospective cohort analysis in a consecutive all-comer population was performed in patients that had a BVS implanted for coronary artery disease (CAD) in vessels with reference diameter <2.75 mm. Primary end-point was the occurrence of BVS failure (any event between target lesion revascularization (TLR) and definite/probable thrombosis) at the longest available follow-up. Secondary end-points were device-oriented clinical outcome (DOCE, a composite of cardiac death, target-vessel non-fatal myocardial infarction (MI) and TLR) and its single components at 12-month follow-up.

Results

A total of 121 patients (133 lesions) were treated between March 2013 and December 2014 at three high volume Italian centers. From baseline clinical and angiographic characteristics emerges a highly complex patient population. Procedural success was obtained in 120 (99.2%) patients. In-hospital events included one cardiac death. At the longest available clinical follow-up (average 12 ± 6, median 11.4 months, interquartile ranges (IQR) 8, primary end-point occurred in 12 patients (9.0%), including 12 (9.0%) TLR and 2 (1.5%) BVS thrombosis. DOCE occurred in 9.0% of cases. The use of overlapping BVS in this setting did not increase the risk of adverse events.

Conclusions

BVS implantation in a highly complex clinical and angiographic setting of small coronary vessels was technically feasible and effective in maintaining vessel patency after 12 months. © 2016 Wiley Periodicals, Inc.

REFERENCES

1Foley DP, Melkert R, Serruys PW. Influence of coronary vessel size on renarrowing process and late angiographic outcome after successful balloon angioplasty. Circulation 1994; 90: 1239–1251.
10.1161/01.CIR.90.3.1239
CAS PubMed Web of Science® Google Scholar
2Morice MC. Stenting for small coronary vessels. J Invasive Cardiol 2003; 15: 377–379.
PubMed Google Scholar
3Elezi S, Dibra A, Mehilli J, Pache J, Wessely R, Schömig A, Kastrati A. Vessel size and outcome after coronary drug-eluting stent placement: Results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents. J Am Coll Cardiol 2006; 48: 1304–1309.
10.1016/j.jacc.2006.05.068
PubMed Web of Science® Google Scholar
4Hermiller JB, Fergus T, Pierson W, Su X, Sood P, Sudhir K, Stone GW. Clinical and angiographic comparison of everolimus-eluting and paclitaxel-eluting stents in small coronary arteries: A post hoc analysis of the SPIRIT III randomized trial. Am Heart J 2009; 158: 1005–1010.
10.1016/j.ahj.2009.09.018
CAS PubMed Web of Science® Google Scholar
5Cortese B, Bertoletti A, De Matteis S, Danzi GB, Kastrati A. Drug-eluting stents perform better than bare metal stents in small coronary vessels: A meta-analysis of randomised and observational clinical studies with mid-term follow up. Int J Cardiol 2012; 161: 73–82.
10.1016/j.ijcard.2011.04.016
PubMed Web of Science® Google Scholar
6Serruys PW, Garcia-Garcia HM, Onuma Y. From metallic cages to transient bioresorbable scaffolds: Change in paradigm of coronary revascularization in the upcoming decade? Eur Heart J 2012; 33: 16–25b.
10.1093/eurheartj/ehr384
PubMed Web of Science® Google Scholar
7Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW, Onuma Y, Garcia-Garcia HM, McGreevy R, Veldhof S. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): A prospective open-label trial. Lancet 2008; 371: 899–907.
10.1016/S0140-6736(08)60415-8
CAS PubMed Web of Science® Google Scholar
8Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-Year outcomes and results from multiple imaging methods. Lancet 2009; 373: 897–910.
10.1016/S0140-6736(09)60325-1
CAS PubMed Web of Science® Google Scholar
9Gomez-Lara J, Garcia-Garcia HM, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, Nieman K, Bruining N, Dorange C, Miquel-Hébert K, Veldhof S, Webster M, Thuesen L, Dudek D. A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents. JACC Cardiovasc Interv 2010; 3: 1190–1198.
10.1016/j.jcin.2010.07.016
PubMed Web of Science® Google Scholar
10Diletti R, Farooq V, Girasis C, Bourantas C, Onuma Y, Heo JH, Gogas BD, van Geuns RJ, Regar E, de Bruyne B, Dudek D, Thuesen L, Chevalier B, McClean D, Windecker S, Whitbourn RJ, Smits P, Koolen J, Meredith I, Li X, Miquel-Hebert K, Veldhof S, Garcia-Garcia HM, Ormiston JA, Serruys PW. Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: Does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial. Heart 2013; 99: 98–105.
10.1136/heartjnl-2012-302598
CAS PubMed Web of Science® Google Scholar
11Capodanno D, Gori T, Nef H, Latib A, Mehilli J, Lesiak M, Caramanno G, Naber C, Di Mario C, Colombo A, Capranzano P, Wiebe J, Araszkiewicz A, Geraci S, Pyxaras S, Mattesini A, Naganuma T, Münzel T, Tamburino C. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: Early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention 2015; 10: 1144–1153.
10.4244/EIJY14M07_11
PubMed Web of Science® Google Scholar
12Ielasi A, Cortese B, Varricchio A, RAI registry investigators. Immediate and midterm outcomes following primary PCI with bioresorbable vascular scaffold implantation in patients with ST-segment myocardial infarction: Insights from the multicentre “Registro ABSORB Italiano” (RAI registry). EuroIntervention 2015; 11: 157–162.
10.4244/EIJY14M10_11
PubMed Web of Science® Google Scholar
13Cortese B, Ielasi A, Romagnoli E, Varricchio A, Cuculo A, Loi B, Pisano F, Corrado D, Sesana M, La Vecchia L, Summaria F, Tespili M, Silva Orrego P, Tognoni G, Steffenino G. Clinical comparison with short-term follow-up of bioresorbable vascular scaffold versus everolimus-eluting stent in primary percutaneous coronary interventions. Am J Cardiol 2015; 116: 705–710.
10.1016/j.amjcard.2015.05.049
CAS PubMed Web of Science® Google Scholar
14Nakatani S, Onuma Y, Ishibashi Y, Muramatsu T, Iqbal J, Zhang YJ, van Geuns RJ, Ormiston JA, Serruys PW. Early (before 6 months), late (6-12 months) and very late (after 12 months) angiographic scaffold restenosis in the ABSORB Cohort B trial. EuroIntervention 2015; 10: 1288–1298.
10.4244/EIJV10I11A218
PubMed Web of Science® Google Scholar
15Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW, Academic Research Consortium. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344–2351.
10.1161/CIRCULATIONAHA.106.685313
PubMed Web of Science® Google Scholar
16Schunkert H, Harrell L, Palacios IF. Implications of small reference vessel diameter in patients undergoing percutaneous coronary revascularization. J Am Coll Cardiol 1999; 34: 40–48.
10.1016/S0735-1097(99)00181-3
CAS PubMed Web of Science® Google Scholar
17Elezi S, Kastrati A, Neumann FJ, Hadamitzky M, Dirschinger J, Schömig A. Vessel size and long-term outcome after coronary stent placement. Circulation 1998; 98: 1875–1880.
10.1161/01.CIR.98.18.1875
CAS PubMed Web of Science® Google Scholar
18Biondi-Zoccai G, Moretti C, Abbate A, Sheiban I. Percutaneous coronary intervention for small vessel coronary artery disease. Cardiovasc Revasc Med 2010; 11: 189–198.
10.1016/j.carrev.2009.04.007
PubMed Google Scholar
19Sanchez OD, Yahagi K, Koppara T, Virmani R, Joner M. The everolimus-eluting Xience stent in small vessel disease: Bench, clinical, and pathology view. Med Devices (Auckl) 2014; 8: 37–45.
PubMed Web of Science® Google Scholar
20Hermiller JB, Rutledge DR, Mao VW, Zhao W, Wang J, Gruberg L, Lombardi W, Sharma SK, Krucoff MW. Clinical outcomes in real-world patients with small vessel disease treated with XIENCE V® everolimus-eluting stents: One year results from the XIENCE V® USA condition of approval post-market study. Catheter Cardiovasc Interv 2014; 84: 7–16.
10.1002/ccd.25325
PubMed Web of Science® Google Scholar
21Caputo R, Leon M, Serruys P, Neumann FJ, Yeung A, Windecker S, Belardi JA, Silber S, Meredith I, Widimský P, Saito S, Mauri L. Performance of the resolute zotarolimus-eluting stent in small vessels. Catheter Cardiovasc Interv 2014; 84: 17–23.
10.1002/ccd.25485
PubMed Web of Science® Google Scholar
22Honda Y, Fitzgerald PJ. Stent expansion as a mechanical parameter to predict late stent patency: Back to the basics. JACC Cardiovasc Interv 2009; 2: 1276–1278.
10.1016/j.jcin.2009.10.013
PubMed Web of Science® Google Scholar
23Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, Litt MR, Kini A, Kabour A, Marx SO, Popma JJ, McGreevy R, Zhang Z, Simonton C, Stone GW, ABSORB III Investigators. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med 2015; 373: 1905–1915.
10.1056/NEJMoa1509038
CAS PubMed Web of Science® Google Scholar
24Woudstra P, Grundeken MJ1, Kraak RP1, Hassell ME, Arkenbout EK, Baan J, Jr, Vis MM, Koch KT, Tijssen JG, Piek JJ, de Winter RJ, Henriques JP, Wykrzykowska JJ. Amsterdam Investigator-initiateD Absorb strategy all-comers trial (AIDA trial): A clinical evaluation comparing the efficacy and performance of ABSORB everolimus-eluting bioresorbable vascular scaffold strategy vs. the XIENCE family (XIENCE PRIME or XIENCE Xpedition) everolimus-eluting coronary stent strategy in the treatment of coronary lesions in consecutive all-comers: Rationale and study design. Am. Heart J 2014; 167: 133–140.
10.1016/j.ahj.2013.09.017
CAS PubMed Web of Science® Google Scholar
25Godino C, Furuichi S, Latib A, Morici N, Chieffo A, Romagnoli E, Tamburino C, Barbagallo R, Cera M, Antoniucci D, Goktekin O, Di Mario C, Reimers B, Grube E, Airoldi F, Sangiorgi GM, Colombo A. Clinical and angiographic follow-up of small vessel lesions treated with paclitaxel-eluting stents (from the TRUE Registry). Am J Cardiol 2008; 102: 1002–1008.
10.1016/j.amjcard.2008.05.052
CAS PubMed Web of Science® Google Scholar
26Farooq V, Serruys PW, Heo JH, Gogas BD, Onuma Y, Perkins LE, Diletti R, Radu MD, Räber L, Bourantas CV, Zhang Y, van Remortel E, Pawar R, Rapoza RJ, Powers JC, van Beusekom HM, Garcìa-Garcìa HM, Virmani R. Intracoronary optical coherence tomography and histology of overlapping everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: The potential implications for clinical practice. JACC Cardiovasc Interv 2013; 6: 523–532.
10.1016/j.jcin.2012.12.131
PubMed Web of Science® Google Scholar
27Farooq V, Onuma Y, Radu M, Okamura T, Gomez-Lara J, Brugaletta S, Gogas BD, van Geuns RJ, Regar E, Schultz C, Windecker S, Lefèvre T, Brueren BR, Powers J, Perkins LL, Rapoza RJ, Virmani R, García-García HM, Serruys PW. Optical coherence tomography (OCT) of overlapping bioresorbable scaffolds: From benchwork to clinical application. EuroIntervention 2011; 7: 386–399.
10.4244/EIJV7I3A64
PubMed Web of Science® Google Scholar

Citing Literature

Volume88, Issue3

September 2016

Pages 380-387

SCAI Member Sign in

Bioresorbable vascular scaffolds for small vessels coronary disease: The BVS-save registry

Abstract

Objective

Background

Methods

Results

Conclusions

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Bioresorbable vascular scaffolds for small vessels coronary disease: The BVS-save registry

Abstract

Objective

Background

Methods

Results

Conclusions

REFERENCES

Citing Literature

References

Related

Information